Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
16:02:41 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:NXTC - NEXTCURE INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NXTC - Q4.81.60·1.640.21.58+0.010.653.1702201.64  1.713  1.562.57  0.9815:42:59Apr 0815 min RT 2¢

Recent Trades - Last 10 of 220
Time ETExPriceChangeVolume
15:42:59Q1.580.01100
15:41:45Q1.610.0469
15:39:48Q1.6250.055100
15:39:17Q1.6250.05531
15:39:10Q1.600.03100
15:39:00Q1.6250.05569
15:38:12Q1.600.031,100
15:38:12Q1.6250.055100
15:38:12Q1.6250.055100
15:32:03Q1.6250.05514

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-08 07:00U:NXTCNews ReleaseNextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024
2024-04-04 07:05U:NXTCNews ReleaseNextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board
2024-04-02 07:00U:NXTCNews ReleaseNextCure to Present at 23rd Annual Needham Virtual Healthcare Conference
2024-03-21 08:55U:NXTCNews ReleaseNextCure Provides Business Update and Reports Full Year 2023 Financial Results
2024-03-05 08:05U:NXTCNews ReleaseNextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances
2024-01-18 16:05U:NXTCNews ReleaseNextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders
2023-12-21 07:05U:NXTCNews ReleaseNextCure Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury
2023-12-14 06:45U:NXTCNews ReleaseNextCure Provides Year-End Clinical Pipeline Updates
2023-11-20 07:00U:NXTCNews ReleaseNextCure to Present at the 35th Annual Piper Sandler Healthcare Conference
2023-11-15 16:05U:NXTCNews ReleaseNextCure Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML
2023-11-02 16:05U:NXTCNews ReleaseNextCure Provides Business Update and Reports Third Quarter 2023 Financial Results
2023-10-17 08:05U:NXTCNews ReleasePreclinical Data Demonstrate Anti-Siglec-15 Treatment Reduced Bone Loss and Enhanced Bone Quality in Mice with Moderate-to-Severe Osteogenesis Imperfecta (OI)
2023-09-26 16:05U:NXTCNews ReleaseNextCure Presents Preclinical Data on NC181, a Novel Therapeutic Candidate Targeting ApoE4, for the Treatment of Alzheimer ¢ € ™s Disease
2023-09-12 08:05U:NXTCNews ReleaseA Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
2023-09-07 16:05U:NXTCNews ReleaseNextCure and Nordic Bioscience Publish Review Article on the Regulation of Tumor Immunity by Tumor Collagen
2023-09-05 16:05U:NXTCNews ReleasePreclinical Data Demonstrate Potential Application of Anti-Siglec-15 Treatment in Bone Disease
2023-08-31 07:00U:NXTCNews ReleaseNextCure to Present at the H.C. Wainwright 25th Annual Global Investment Conference
2023-08-03 16:05U:NXTCNews ReleaseNextCure Provides Business Update and Reports Second Quarter 2023 Financial Results
2023-06-21 16:05U:NXTCNews ReleaseNextCure Presents Non-Clinical Data Defining the Mechanism of NC525 at the 2023 Federation of Clinical Immunology Societies (FOCIS) Annual Meeting
2023-05-09 07:00U:NXTCNews ReleaseNextCure to Present at the JMP Securities Life Sciences Conference